ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01CD02 | B | Docetaxel (trihydrated) - 20mg/ml | 11068 | 81822/1 | TAXOTERE | 20mg/ml | 1 x 0.5ml + 1.5ml | Injectable concentrated solution+diluent | Infusion | Mersaco | Sanofi Aventis Deutschland GmbH | Germany | 6,574,078 L.L | 23.08 | B | Sanofi Mature IP | France | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L01CD02 | B | Docetaxel (trihydrated) - 20mg/ml | 1780 | 208396/97 | TAXOTERE | 20mg/ml | 1 x 0.5ml + 1.5ml | Injectable concentrated solution+diluent | Infusion | Mersaco | Sanofi Aventis Deutschland GmbH | Germany | 6,574,078 L.L | 23.08 | B | Aventis Pharma SA | France | 2/5/2024 | 0 |
L01CD02 | G | Docetaxel - 20mg/ml | 8734 | 56816/1 | DOCETAXEL ACCORD | 20mg/1ml | 1 | Injectable concentrate for solution | Infusion | Mediterranean Pharmaceutical Company | Accord Healthcare Limited | UK | 4,110,814 L.L | 23.08 | B | Accord Healthcare Limited | UK | 2/5/2024 | 0 |
L01CD02 | G | Docetaxel - 20mg/2ml | 5867 | 218936/10 | DOCETAXEL EBEWE | 20mg/2ml | 1 | Injectable solution | Infusion | Khalil Fattal & Fils S.A.L. | Fareva Unterach GmbH | Austria | 5,313,553 L.L | 23.08 | B | Ebewe Pharma GesmbH.NFG.KG | Austria | 2/5/2024 | 0 |
L01CD02 | G | Docetaxel - 40mg/ml | 3576 | 194595/04 | DOCETAXEL GP PHARM | 20mg/0.5ml | 1 x 0.5ml + 1.5ml | Injectable concentrated solution+diluent | Infusion | Mediterranean Pharmaceutical Company | GP-Pharm, SA | Argentine | 4,567,721 L.L | 23.08 | B | 2/5/2024 | 0 |